Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05421858 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
A Phase 3 study of Candidemia and Candidiasis, Invasive, sponsored by Basilea Pharmaceutica.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
- 20
- Study locations
NCT05421858 is a Phase 3 study of Candidemia and Candidiasis, Invasive that is actively recruiting participants, run by Basilea Pharmaceutica. The registered enrollment target is 450 participants, above the 358-participant average among 8 other Candidemia trials with a reported enrollment target (26% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT05421858, a Phase 3 study of Candidemia and Candidiasis, Invasive, is actively recruiting participants, sponsored by Basilea Pharmaceutica.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Fosmanogepix) for the potential treatment of candidemia and/or invasive candidiasis, a life-threatening fungal infection caused by several species of yeast called Candida. The study is seeking patients who have a diagnosis of candidemia and/or invasive candidiasis. Two-thirds of all patients will receive the study medication fosmanogepix Intravenous (IV) infusion followed by optional fosmanogepix tablets. One-third of all patients will receive a standard of care regimen of caspofungin Intravenous (IV) infusion followed by optional fluconazole capsules. Fosmanogepix or caspofungin will first be given as an Intravenous (IV) infusion directly into a vein in the arm each day at the study clinic. Fosmanogepix tablets or fluconazole capsules will be taken orally by mouth daily either at the study clinic, or at home if patients are well enough to be discharged from the hospital. The treatment effect in patients receiving fosmanogepix to those receiving caspofungin/ fluconazole will be compared. The primary aim is to show that fosmanogepix is not inferior (not worse) to caspofungin/ fluconazole with a noninferiority margin of 15%. The duration of study treatment and number of study visits will vary depending on how long the patient will be treated for the infection. Treatment will continue for a maximum of 6 weeks depending on when the infection is cleared and whether other symptoms related to the infection have improved. There will also be a follow-up visit 6 weeks after the study treatment was stopped.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Fluconazole
- DRUG Fosmanogepix
- DRUG Caspofungin
Study Locations (20)
California
- City of Hope - Duarte
- David Geffen School of Medicine at UCLA - Los Angeles
- UC Davis Medical Center - Sacramento
Michigan
- University of Michigan Health System (UMHS) - A. Alfred Taubman Health Care Center - Ann Arbor
- DMC Harper University Hospital - Detroit
- Henry Ford Hospital, Department of Medicine, Division of Infectious Diseases - Detroit
Georgia
- Emory University Hospital - Clifton Road - Atlanta
- Augusta University Medical Center - Augusta
Pennsylvania
- University of Pennsylvania School of Medicine - Philadelphia
- UPMC Presbyterian - Pittsburgh
Texas
- Houston Methodist Hospital - Texas Medical Center - Houston
- The University of Texas Health Science Center at Houston - Houston
Alabama
- University of Alabama at Birmingham School of Medicine, Department of Medicine - Birmingham
Indiana
- Indiana University Methodist Hospital - Indianapolis
Kentucky
- University of Kentucky College of Medicine - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2024-12-11 |
| Est. Completion | 2028-01-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05421858
The ClinicalTrials.gov registry entry for NCT05421858 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 358-participant average among 8 other Candidemia trials with a reported enrollment target (26% higher). The listed sponsor is Basilea Pharmaceutica, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Candidemia appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT05421858 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Michigan, Georgia.
Frequently Asked Questions
What is clinical trial NCT05421858 about?
NCT05421858 is a clinical study titled "A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.". The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Fosmanogepix) for the potential treatment of candidemia and/or invasive candidiasis, a life-threatening fungal infection caused by several species of yeast called Candida. The study is seeking ...
What is the current status of trial NCT05421858?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2024-12-11. Estimated completion is 2028-01-30.
What conditions does trial NCT05421858 study?
This clinical trial studies the following conditions: Candidemia, Candidiasis, Invasive.
What interventions are being tested in trial NCT05421858?
The interventions under investigation include: Placebo (DRUG), Fluconazole (DRUG), Fosmanogepix (DRUG), Caspofungin (DRUG).
Who is sponsoring clinical trial NCT05421858?
This trial is sponsored by Basilea Pharmaceutica, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05421858 being conducted?
This trial has 20 study locations across Alabama, California, Georgia, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Candidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
ACTIVE NOT RECRUITING · Phase 3
-
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
COMPLETED · Phase 3
-
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
COMPLETED · Phase 3
-
Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia
RECRUITING · Phase 2
-
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
COMPLETED · Phase 1
-
Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.